AELIA

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain, focused on developing a functional cure for HIV infection. The company's primary asset is the HTI (HIVACAT T-cell Immunogen) vaccine, which is designed to stimulate a potent T-cell response against vulnerable parts of the virus. By utilizing a combination of DNA, viral vectors (MVA), and chimpanzee adenovirus (ChAdOx1) delivery systems, AELIX aims to enable HIV-infected individuals to control the virus without the need for lifelong antiretroviral therapy. The company has successfully completed Phase 1 and Phase 2a clinical trials, demonstrating the safety and immunogenicity of its therapeutic vaccine candidates.